PMC7453436_01
(a) and (b) Patient 48 h after receiving high-dose tigecycline, (c) and (d) Patient 10 days after reverting to the conventional dose of tigecycline.
10.1177_2049936120952605-fig1.jpg
PMC7453436_01_10.1177_2049936120952605-fig1.jpg
fig1-2049936120952605
After 48 h of increasing tigecycline dose, the patient developed generalized diffuse cutaneous hyperpigmentation, most notably on the lips, hands, thighs, neck, and anterior trunk (Figure 1(a) and (b)). The patient continued the conventional dose of tigecycline for 24 days, with gradual convalescence in skin discoloration (Figure 1(c) and (d)).
Skin section obtained from a skin punch biopsy from the right thigh of the patient 20 days after tigecycline dose reduction. (Hematoxylin and eosin, (a) original magnification x100, (b) original magnification x200.)
10.1177_2049936120952605-fig2.jpg
PMC7453436_01_10.1177_2049936120952605-fig2.jpg
fig2-2049936120952605
No histological features suggestive of ischemia were observed (Figure 2).